AISLING CAPITAL MANAGEMENT LP other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}

Adviser Profile

As of Date:

03/28/2024

Adviser Type:

- Large advisory firm


Number of Employees:

12

of those in investment advisory functions:

8


Registration:

SEC, Approved, 9/21/2015

AUM:

515,733,599 55.03%

of that, discretionary:

515,733,599 55.03%

GAV:

510,615,421 55.90%

Avg Account Size:

171,911,200 55.03%


SMA’s:

NO

Private Funds:

2

Contact Info

212 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
789M 677M 564M 451M 338M 226M 113M
2016 2017 2018 2019 2020 2021 2022 2023

Recent News

Marker Therapeutics Inc.
04/01/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

ADMA Biologics Inc.
04/01/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

The Baupost Group
03/29/2021

The Weekly Notable Startup Funding Report takes us on a trip across various ecosystems in the US, highlighting some of the notable funding activity in the various markets that we track. The notable startup funding rounds for the week ending 3/27/21 ...

alleywatch.com

Zosano Pharma Corporation (NASDAQ:ZSAN) Drops -9.49% in a week: What’s Hurting the Stock?
03/26/2021

In last trading session, Zosano Pharma Corporation (NASDAQ:ZSAN) saw 2,995,253 shares changing hands with its beta currently measuring 3.98. Company’s recent per share price level of $1.24 trading at $0.

marketingsentinel.com

Monte Rosa Therapeutics Raises $95M in Series C Financing
03/16/2021

The round was led by Avoro Capital Advisors with participation from additional new investors Fidelity Management & Research Company LLC, funds and accounts managed by BlackRock, funds and accounts ...

finsmes.com


Private Funds Structure

Fund Type Count GAV
Private Equity Fund 2 $510,615,421

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
MOMENTUM ADVISORS, LLC - - 6.2m - - - - 6.2m 353.1m 1
YOUR ADVOCATES, LTD., LLP - - - - - - - - 362.2m -
PROVENANCE MANAGEMENT CO., LP - - 281.4m - - - - 281.4m 350.3m 6
CIMARRON HEALTHCARE CAPITAL, LLC - - 393.0m - - - - 393.0m 400.0m 7
RALLYDAY PARTNERS, LLC - - 329.0m - - - - 329.0m 329.0m 4
VERSA CAPITAL MANAGEMENT, L.P. - - 267.1m - - - - 267.1m 267.4m 7
1801 ADMIN, LLC - - 267.4m - - - - 267.4m 267.4m 7
PSC CAPITAL PARTNERS LLC - - 301.0m - - - - 301.0m 301.0m 6
TURNBRIDGE CAPITAL, LLC - - 305.9m - - - - 305.9m 319.6m 5
COALESCE CAPITAL MANAGEMENT LLC - - 800.8m - - - - 800.8m 800.8m 5

Private Funds



Employees




Brochure Summary

Overview

A. Aisling, a Delaware limited partnership formed on August 25, 2015, is an investment adviser located in New York, NY. Aisling’s general partner is Aisling Capital Partners IV LLC, a Delaware limited liability company (the “General Partner”). Aisling is principally owned by its two co-presidents, Andrew N. Schiff and Steven A. Elms. B. As an investment adviser, Aisling provides investment advisory services to pooled investment vehicles, Aisling Capital IV, LP and Aisling Capital V, LP (together with any other private investment funds managed by Aisling, including future funds, the “Funds” and each, a “Fund”), as well as co-investment vehicles formed in connection therewith. The Funds are exempt from registration under the Investment Company Act of 1940, as amended (the “Investment Company Act”), pursuant to Section 3(c)(7) of the Investment Company Act. The general partner of Aisling Capital IV, LP is Aisling Capital Partners IV, LP, a Delaware limited partnership, and the general partner of Aisling Capital V, LP is Aisling Capital Partners V, LP, a Delaware limited partnership (each a “Fund GP” and together, the “Fund GPs”). The Fund GPs and Aisling are affiliates. The Fund GPs are registered under the Advisers Act pursuant to Aisling’s registration in accordance with SEC guidance. This Brochure also describes the business practices of the Fund GPs, which operate as a single advisory business together with Aisling. Aisling provides discretionary investment management services to the Funds pursuant to each Fund’s respective investment management agreement with Aisling. Aisling manages the assets of the Funds in accordance with the limited partnership agreement (“Partnership Agreement”) for each Fund, the Confidential Private Placement Memorandum (“PPM”) for each Fund and related agreements (together with the Partnership Agreement and PPM, are referred to herein as the “Offering Documents”). The Firm’s investment objective is to make investments in companies developing and commercializing important and innovative healthcare products, services and technologies, across a range of financial instruments. The Firm pursues a multi-strategy investment approach, and may invest in private companies, public companies, equity, debt and other structured securities. The Firm generally seeks to make non-control investments. Information about Aisling’s advisory services is included in this Brochure and
is qualified in its entirety by information contained in the relevant Fund’s Offering Documents. C. Aisling does not tailor its advisory services to the individual or particular needs of investors in the Funds. Such investors will accept the terms of advisory services as set forth in the relevant Offering Documents. The Firm has broad investment authority with respect to the Funds and, as such, investors should consider whether the investment objectives of a Fund will be in line with their respective individual objectives and risk tolerance prior to investment. The Funds or the general partners of such Funds have entered and may in the future enter into side letters or other written agreements with certain investors that have the effect of establishing rights or provisions under, or altering or supplementing, the terms of a Fund’s partnership agreement or an investor’s subscription agreement with respect to such investor. Such provisions have included and may include, without limitation, rights with respect to fees, expenses, disclosure or priority on co-investment opportunities, distributions, excuse or exclusion from investments, transfers of interests in the Fund, tax and other reporting, notice requirements, sharing of investment ideas, introductions to business persons and opportunities, and other representations, warranties or diligence confirmations. Other side letter rights are likely to confer benefits on the relevant investor at the expense of the relevant Fund or of investors as a whole, including in the event that a side letter confers additional reporting, information rights and/or transfer rights, the costs and expenses of which are expected to be borne by the relevant Fund. For the most part, any rights established, or any terms altered or supplemented will govern only the investment of the specific investor and not the terms of a Fund as whole. Certain additional rights but not all rights, terms or conditions could be elected by certain sizeable investors with “most favored nations” rights pursuant to a Fund’s limited partnership agreement. Aisling in certain circumstances will not be required to notify other limited partners of any such side letters or of any of the rights or terms or provisions thereof. D. Aisling does not participate in wrap fee programs. E. As of December 31, 2022 Aisling had assets under discretionary management of approximately $332,674,494.